Clinical trial

Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback

Name
IRB_00030810
Description
Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively sets the level of vascular tone. With advancing age and in many disease states, deleterious adaptations in the production and sensitivity of these vasodilator and vasoconstrictor substances may be observed, leading to a reduction in skeletal muscle blood flow and compromised perfusion to the muscle tissue. Adequate perfusion is particularly important during exercise to meet the increased metabolic demand of the exercising tissue, and thus any condition that reduces tissue perfusion may limit the capacity for physical activity. As it is now well established that regular physical activity is a key component in maintaining cardiovascular health with advancing age, there is a clear need for further studies in populations where vascular dysfunction is compromised, with the goal of identifying the mechanisms responsible for the dysfunction and exploring whether these maladaptations may be remediable. Thus, to better understand the etiology of these vascular adaptations in health and disease, the current proposal is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease. While there are clearly a host of vasoactive substances which collectively act to govern vasoconstriction both at rest and during exercise, four specific pathways that may be implicated have been identified in these populations: Angiotensin-II (ANG-II), Endothelin-1 (ET-1), Nitric Oxide (NO), and oxidative stress.
Trial arms
Trial start
2008-09-01
Estimated PCD
2025-08-01
Trial end
2025-08-01
Status
Recruiting
Phase
Early phase I
Treatment
Maximum Exercise Tests
Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
Arms:
Chronic Obstructive Pulmonary Disease patients, Coronary Angiography patients, Healthy Older Controls (over 65 years), Healthy Young Volunteers (18-30 years), Heart Failure patients, Hypertension patients, Pulmonary Arterial Hypertension patients
BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
Arms:
Chronic Obstructive Pulmonary Disease patients, Coronary Angiography patients, Healthy Older Controls (over 65 years), Healthy Young Volunteers (18-30 years), Heart Failure patients, Hypertension patients, Pulmonary Arterial Hypertension patients
BQ-123
Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
Arms:
Chronic Obstructive Pulmonary Disease patients, Coronary Angiography patients, Healthy Older Controls (over 65 years), Healthy Young Volunteers (18-30 years), Heart Failure patients, Hypertension patients, Pulmonary Arterial Hypertension patients
Fexofenadine, Ranitidine
Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
Arms:
Chronic Obstructive Pulmonary Disease patients, Coronary Angiography patients, Healthy Older Controls (over 65 years), Healthy Young Volunteers (18-30 years), Heart Failure patients, Hypertension patients, Pulmonary Arterial Hypertension patients
Other names:
Allegra, Zantac
Angiotensin-II, Valsartan
Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
Arms:
Chronic Obstructive Pulmonary Disease patients, Coronary Angiography patients, Healthy Older Controls (over 65 years), Healthy Young Volunteers (18-30 years), Heart Failure patients, Hypertension patients, Pulmonary Arterial Hypertension patients
Other names:
Diovan
Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine
Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
Arms:
Chronic Obstructive Pulmonary Disease patients, Coronary Angiography patients, Healthy Older Controls (over 65 years), Healthy Young Volunteers (18-30 years), Heart Failure patients, Hypertension patients, Pulmonary Arterial Hypertension patients
Other names:
Regitine
BQ-123, MitoQ, BH4
Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
Arms:
Chronic Obstructive Pulmonary Disease patients, Coronary Angiography patients, Healthy Older Controls (over 65 years), Healthy Young Volunteers (18-30 years), Heart Failure patients, Hypertension patients, Pulmonary Arterial Hypertension patients
Size
420
Primary endpoint
Change in Limb Blood Flow
Baseline and 1 hour
Eligibility criteria
Inclusion Criteria: * Healthy Young Volunteers: 18-30 years of age with no diseases or conditions that would affect their participation in the study * Healthy Older Controls: volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study * Coronary Angiography subjects: patients undergoing routine coronary angiography * Chronic Obstructive Pulmonary Disease subjects: patients diagnosed with mild to moderate COPD * Pulmonary Arterial Hypertension subjects: patients with idiopathic or heritable Group 1 pulmonary arterial hypertension * Heart Failure subjects: patients with Class I, II or III New York Heart Association symptoms of Heart Failure * Hypertension subjects: patients diagnosed with chronic high blood pressure Exclusion Criteria: * Severe COPD (use of supplemental oxygen, or have a one-second forced expiratory volume of less than 30% predicted) * History of myocardial infarction * History of percutaneous coronary revascularization * History of coronary artery bypass grafting * Unstable angina pectoris * History of variant angina * Ejection fraction \< 50% * Significant renal disease (Glomerular Filtration Rate \< 50 mL/min/1.73m2) * Subjects whose medical care or safety may be at risk from undergoing a Magnetic Resonance Imaging examination (e.g. pacemaker, metal implants, certain types of heart valves) * Subject is pregnant * Subject has physical ailments (other than COPD, PAH, HF, or hypertension) that would prevent them from study participation in the judgment of the investigator
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 420, 'type': 'ESTIMATED'}}
Updated at
2023-10-11

1 organization

4 products

4 indications

Organization
Russell Richardson
Product
BH4
Indication
Hypertension
Product
BQ-123